FIELD: genetic engineering.
SUBSTANCE: invention relates to genetic engineering, specifically to the production of traps of a hepatitis C virus in the form of recombinant chimeric proteins; it can be used in medical diagnostics for detection of a hepatitis C virus in biological fluids. Recombinant chimeric protein CD81-SAA is developed, having the capability of binding virions of the hepatitis C virus, which contains an amino acid sequence of a large extracellular loop of a human CD81 receptor, fused with an amino acid sequence of streptavidin. Moreover, an oligo-histidine sequence was also included in the protein structure for provision of a possibility of isolation of protein on a nickel-agarose sorbent. Microparticles consisting of lactic acid polymer, to the surface of which the created recombinant protein is covalently attached, are also proposed. Preliminary biotinylating of polymer microparticles allowed for more efficient formation of conglomerates due to high affinity of biotin to streptavidin included in recombinant protein.
EFFECT: invention provides for the production of protein capable of binding virions of a hepatitis C virus due to specific interaction of CD81 with protein E2 of a viral capsid.
3 cl, 6 dwg, 11 ex
